Research recommends the concurrent use of specific probiotics whilst undergoing antibiotic treatment.  In excess of 500 peer reviewed research papers have demonstrated the clinical efficacy of the probiotic yeast Saccharomyces boulardii to preserve gastrointestinal homeostasis.

Known benefits of supplementing S. boulardii during a course of antibiotics include:

  • Prevention and treatment of diarrhoea
  • Prevention and treatment of Clostridium difficile infection
  • Inhibition of Candida albicans which may reduce the incidence of thrush
  • Regulation of intestinal microbial homeostasis

S.boulardii is a yeast, not a bacteria which allows it to effectively prevent these complications commonly experienced during a course of antibiotic treatment, without the antibiotics affecting the organism.

 

Not all probiotic supplements are equal. Knowing the colony forming units (CFU) count of Saccharomyces boulardii is of utmost importance when we prescribe S. boulardii. This is because the milligram quantity does not always capture the CFU count. For example, a comparative study referenced in the World Journal of Gastroenterology found that when six S. boulardii products were tested, 50% did not meet the amount of S. boulardii stated on their label.  This miscommunication is avoidable when a direct CFU count is declared on the label instead. By only providing the milligram dose, the CFU cannot be guaranteed and can undergo degradation over time. The S.Boulardii product we recommend guarantees 5 billion live colony forming units up until the date of expiry.